Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing.

Abstract

Despite its function as an inhibitor of urokinase and tissue-type plasminogen activator (PA), PA inhibitor-1 (PAI-1) has a paradoxical protumorigenic role in cancer, promoting angiogenesis and tumor cell survival. In this review, we summarize preclinical evidence in support of the protumorigenic function of PAI-1 that has led to the testing of small-molecule PAI-1 inhibitors, initially developed as antithrombotic agents, in animal models of cancer. The review discusses the challenges and the opportunities that lay ahead to the development of efficacious and nontoxic PAI-1 inhibitors as anticancer agents.

• Authors: Veronica R Placencio, Yves A DeClerck
• Journal: Cancer research (Cancer Res) Vol. 75 Issue 15 Pg. 2969-74 (Aug 01 2015) ISSN: 1538-7445 [Electronic] United States
• PMID: 26180080 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
• Copyright: ©2015 American Association for Cancer Research.

Chemical References

• Antineoplastic Agents
• Plasminogen Activator Inhibitor 1
• SERPINE1 protein, human

Topics

• Animals
• Antineoplastic Agents (pharmacology)
• Apoptosis (physiology)
• Disease Models, Animal
• Humans
• Mice
• Molecular Targeted Therapy (methods)
• Neoplasms (drug therapy, pathology)
• Neovascularization, Pathologic (drug therapy)
• Plasminogen Activator Inhibitor 1 (metabolism, physiology)